Several companies working in the burgeoning field of immuno-oncology have staged IPOs this year, and at least two more are on the way. But will enthusiastic investors be patient enough to see a payoff?
Immuno-Oncology Players Gritstone And Sutro Join The Biotech IPO Frenzy
